Blood test could replace gadolinium scans for MS monitoring
NCT ID NCT07292480
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether monthly blood tests for a nerve damage marker (neurofilament light chain) can detect hidden disease activity in people with relapsing-remitting multiple sclerosis (MS) earlier than standard yearly MRI scans. The goal is to reduce the need for gadolinium-based contrast agents in MRI and allow faster treatment adjustments. The study will compare 84 participants on monthly blood monitoring against standard care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
monthly blood test for neurofilament light chain (pNfL)
What this could lead to
If successful, this could lead to a simpler, safer way to monitor MS and catch silent disease activity early, allowing faster treatment changes.
What could go wrong
This is a small, early-phase study. The blood test may not reliably detect all hidden activity, and results may not change long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS (MS) - RELAPSING-REMITTING are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Nice
RECRUITINGNice, France
Contact Email: •••••@•••••
-
CHU de Nîmes
RECRUITINGNîmes, France
Contact Phone: •••-•••-•••• Email: •••••@•••••